		TEIVISE DISC	LOSONE I ONIVI	
Dat	te: <u>March 31st, 2022</u>			
		liang Zhu		
			.T1) differentially regulates gluconeogenesis and GLP-	- 1
			a preliminary validation of the hypothesis of "SGLT	
	dge" as an indication for "s			-
	nuscript number (if known			
rela par to t	ated to the content of your rties whose interests may b	manuscript. "Related" me be affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that and an any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the manuscript. If you are in doubt about whether to list a o so.	
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to t	•	tension, you should declare	defined broadly. For example, if your manuscript per all relationships with manufacturers of antihypertens the manuscript.	
	tem #1 below, report all su time frame for disclosure	• •	ed in this manuscript without time limit. For all other	tems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate none (add rows as needed)	institution)	
		Time frame: Since the initia	al planning of the work	
	All support for the present	X None		
	manuscript (e.g., funding, provision of study materials,	None		

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for	<u>X</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Support for attending meetings and/or travel	<u>X</u> None	
8	Patents planned, issued or	<u>X</u> None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>X</u> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> _None	
12	Description of a series and		
12	Receipt of equipment, materials, drugs, medical	<u>X</u> None	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the fo	llowing box:

Your Name:	Huajie Cai
Manuscript Title: <u>Sodiu</u>	ım-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-
receptor (GLP-1R) expre	ession in different diabetic rats: a preliminary validation of the hypothesis of "SGLT
bridge" as an indication	for "surgical diabetes"
Manuscript number (if k	(nown): <u>ATM-22-1769</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	XNone	
4	Consulting fees	<u>X</u> None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events X None				
speakers bureaus, manuscript writing or educational events 6	5		XNone	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial interests X None				
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services A None X None				
Support for attending meetings and/or travel				
The support for attending meetings and/or travel Support for attending meetings and/or travel				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests None X None	6		X None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests		testimony		
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests				
Pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None	7		XNone	
Pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None				
Pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None	8		X None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None				
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests None X None X None X None	9		X None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests 14 None X None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None		Advisory Board		
committee or advocacy group, paid or unpaid 11 Stock or stock options X None Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None X None X None	10		X None	
group, paid or unpaid 11 Stock or stock options X None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None X None X None				
11 Stock or stock options X None		•		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None	11		V N	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None	11	Stock of Stock options	<u>X</u> None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None	12	Descipt of agricument	V. Name	
writing, gifts or other services 13 Other financial or non-financial interests X None X None	12		<u>X</u> None	
services Other financial or non-financial interests X_None				
13 Other financial or non-financial interests None X None				
financial interests	13		X None	
		financial interests		
	DI-	aco cummovino the charre	onflict of interest in the	fallowing how

The author Huajie Cai has no conflicts of interest to declare.	

Please place an "X" next to the following statement to indicate your agreement:

		10.1.152 2.1502		
Date: <u>Marc</u>				
Your Name: _	Xiaok	un Wang		_
•			(1) differentially regulates gluconeogenesis and GLP-1 a preliminary validation of the hypothesis of "SGLT1	-
		urgical diabetes"		·
):ATM-22-1769		
In the interest	t of transparency	, we ask you to disclose all	relationships/activities/interests listed below that are	e
	• •	•	ins any relation with for-profit or not-for-profit third	
	•		f the manuscript. Disclosure represents a commitmen	t
•	•	•	If you are in doubt about whether to list a	•
•	•	it is preferable that you do	•	
• •	,			
The following manuscript or		to the author's relationship	ps/activities/interests as they relate to the <u>current</u>	
to the epidem	niology of hypert	-	defined broadly. For example, if your manuscript pertall relationships with manufacturers of antihypertension he manuscript.	
	•	pport for the work reported s the past 36 months.	d in this manuscript without time limit. For all other it	tems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initial	planning of the work	
1 All support	for the present	X None		

Time frame: past 36 months

X__None

X None

_None

X

manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)

No time limit for this item.

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

3

any entity (if not indicated

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events X None				
speakers bureaus, manuscript writing or educational events 6	5		XNone	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial interests X None				
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services A None X None				
Support for attending meetings and/or travel				
The support for attending meetings and/or travel Support for attending meetings and/or travel				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests None X None	6		X None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests		testimony		
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests				
Pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None	7		XNone	
Pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None				
Pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None	8		X None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None				
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests None X None X None X None	9		X None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests 14 None X None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None		Advisory Board		
committee or advocacy group, paid or unpaid 11 Stock or stock options X None Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None X None X None	10		X None	
group, paid or unpaid 11 Stock or stock options X None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None X None X None				
11 Stock or stock options X None		•		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None	11		V N	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None	11	Stock of Stock options	<u>X</u> None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None	12	Descipt of agricument	V. Name	
writing, gifts or other services 13 Other financial or non-financial interests X None X None	12		<u>X</u> None	
services Other financial or non-financial interests X_None				
13 Other financial or non-financial interests None X None				
financial interests	13		X None	
		financial interests		
	DI-	aco cummovino the charre	onflict of interest in the	fallowing how

author Xiaokun Wang has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Your Name:	Tao Chen	
Manuscript Title	: Sodium-glucose	co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1
receptor (GLP-1	R) expression in d	ifferent diabetic rats: a preliminary validation of the hypothesis of "SGLT1
bridge" as an inc	lication for "surgic	al diabetes"_
Manuscript num	ber (if known):	ATM-22-1769
related to the co	ntent of your man	ask you to disclose all relationships/activities/interests listed below that are uscript. "Related" means any relation with for-profit or not-for-profit third

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>X</u> None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	<u>X</u> None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	X None		
	testimony			
7	Support for attending meetings and/or travel	<u>X</u> None		
8	Patents planned, issued or	X None		
	pending			
9	Participation on a Data	X None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	<u>X</u> None		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid	Y		
11	Stock or stock options	<u>X</u> _None		
12	Receipt of equipment,	X None		
12	materials, drugs, medical	<u>X</u> _None		
	writing, gifts or other			
	services			
13	Other financial or non-	<u>X</u> _None		
	financial interests			
DI-	Disease summersing the above conflict of interest in the following boy.			

The author Tac	Chen has no c	onflicts of inte	erest to declare.		

Please place an "X" next to the following statement to indicate your agreement:

10.7.12 2.10	
Date:March 31st, 2022	
Your Name: Chaohui Zhen	
	LT1) differentially regulates gluconeogenesis and GLP-1: a preliminary validation of the hypothesis of "SGLT1"
bridge" as an indication for "surgical diabetes"	
Manuscript number (if known): <u>ATM-22-1769</u>	
related to the content of your manuscript. "Related" me	of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a
The following questions apply to the author's relationsl manuscript only.	nips/activities/interests as they relate to the current
-	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.
In item #1 below, report all support for the work report the time frame for disclosure is the past 36 months.	red in this manuscript without time limit. For all other items
Name all entities with	Specifications/Comments
whom you have this	(e.g., if payments were made to you or to your
relationship or indicate	institution)
none (add rows as	
needed)	
Time frame: Since the initi	al planning of the work
All average of fourther proposed.	

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	None	
4	Consulting fees	X None	

5	Payment or honoraria for	<u>X</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Support for attending meetings and/or travel	<u>X</u> None	
8	Patents planned, issued or	<u>X</u> None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>X</u> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> _None	
12	Description of a series and		
12	Receipt of equipment, materials, drugs, medical	<u>X</u> None	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the fo	llowing box:

The author Chaohui Zhen has no conflicts of interest to declare.	

Da	te: <u>March 31st, 2022</u>					
Yo	ur Name: <u>Zhenz</u>	han Zhang				
Ma	Manuscript Title: Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1					
rec	receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of "SGLT1					
	dge" as an indication for "su					
Ma	nuscript number (if known)	:ATM-22-1769				
rela par to	ated to the content of your ries whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment is. If you are in doubt about whether to list a lo so.			
	e following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the current			
to i	the epidemiology of hypertodication, even if that medic	ension, you should declar ation is not mentioned in pport for the work report	e defined broadly. For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items,			
		A1 11 121 111	0 15 11 10			
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		Time frame: Since the initia	al planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone				
		Time frame: pas	st 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None				
3	Royalties or licenses	<u>X</u> None				

Consulting fees

X__None

5	Payment or honoraria for	<u>X</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Support for attending meetings and/or travel	<u>X</u> None	
8	Patents planned, issued or	<u>X</u> None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>X</u> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> _None	
12	Description of a serious and		
12	Receipt of equipment, materials, drugs, medical	<u>X</u> None	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the fo	llowing box:

The author Zhenzhan Zhang has no conflicts of interest to declare.	

Da	Date:March 31st, 2022					
Yo	Your Name: Xiaojiao Ruan					
	Manuscript Title: Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1					
			a preliminary validation of the hypothesis of "SGLT1			
	dge" as an indication for "su					
Ma	nuscript number (if known)	:ATM-22-1769				
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content one necessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a poso.			
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>			
to	• -	ension, you should declare	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.			
	item #1 below, report all sup e time frame for disclosure is		d in this manuscript without time limit. For all other iten	ns,		
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		Time frame: Since the initia	l planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone				
	No time limit for this item.					
2	Crants or contracts from	Time frame: past	36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone				
3	Royalties or licenses	X None				

Consulting fees

X__None

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events X None				
speakers bureaus, manuscript writing or educational events 6	5		XNone	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial interests X None				
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services A None X None				
Support for attending meetings and/or travel				
The support for attending meetings and/or travel Support for attending meetings and/or travel				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests None X None	6		X None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests		testimony		
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests				
Pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None	7		XNone	
Pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None				
Pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None	8		X None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None				
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests None X None X None X None	9		X None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests 14 None X None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None		Advisory Board		
committee or advocacy group, paid or unpaid 11 Stock or stock options X None Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None X None X None	10		X None	
group, paid or unpaid 11 Stock or stock options X None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None X None X None				
11 Stock or stock options X None		•		
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests X None	11		V N	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None	11	Stock of Stock options	<u>X</u> None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests X None	12	Descipt of agricument	V. Name	
writing, gifts or other services 13 Other financial or non-financial interests X None X None	12		<u>X</u> None	
services Other financial or non-financial interests X_None				
13 Other financial or non-financial interests None X None				
financial interests	13		X None	
		financial interests		
	DI-	aco cummovino the charre	onflict of interest in the	fallowing how

The author Xiaojiao Ruan has no conflicts of interest to declare.	

Please place an "X" next to the following statement to indicate your agreement:

Data. Mayab 21st 20	22
Date: <u>March 31st, 20</u> 2	
Manuscript Title: <u>Sodiu</u>	m-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1
receptor (GLP-1R) expre	ession in different diabetic rats: a preliminary validation of the hypothesis of "SGLT1
bridge" as an indication	for "surgical diabetes"
Manuscript number (if k	(nown): ATM-22-1769
related to the content or parties whose interests to to transparency and doe	arency, we ask you to disclose all relationships/activities/interests listed below that are f your manuscript. "Related" means any relation with for-profit or not-for-profit third may be affected by the content of the manuscript. Disclosure represents a commitment so not necessarily indicate a bias. If you are in doubt about whether to list a terest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone			
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone			
3	Royalties or licenses	<u>X</u> None			
4	Consulting fees	XNone			

5	Payment or honoraria for	<u>X</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>X</u> None	
	testimony		
7	Support for attending meetings and/or travel	<u>X</u> None	
8	Patents planned, issued or	<u>X</u> None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>X</u> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>X</u> _None	
12	Description of a serious and		
12	Receipt of equipment, materials, drugs, medical	<u>X</u> None	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the fo	llowing box:

The author Guoxin	Li has no conflicts o	f interest to declare.	